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Mouse cytomegalovirus (MCMV), a-herpesvirus that estab-
lishes latent and persistent infections in mice, is a valuable
model for studying complex virus-host interactions. MCMV
encodes the m145 family of putative immunoevasins with pre-
dictedmajor histocompatibility complex, class I (MHC-I) struc-
ture. Functions attributed to some family members include
down-regulation of host MHC-I (m152) and NKG2D ligands
(m145,m152, andm155) and interactionwith inhibitory or acti-
vating NK receptors (m157). We present the cellular, biochem-
ical, and structural characterization of m153, which is a heavily
glycosylated homodimer, that does not require 2m or peptide
and is expressed at the surface ofMCMV-infected cells. Its 2.4-A˚
crystal structure confirms that this compact molecule preserves
an MHC-I-like fold and reveals a novel mode of dimerization,
confirmed by site-directed mutagenesis, and a distinctive disul-
fide-stabilized extended N terminus. The structure provides a
useful framework for comparative analysis of the divergent
members of the m145 family.
A major strategy for immune evasion, employed by the
large DNA viruses like herpes- and poxviruses, is the expres-
sion of a variety of molecules that attenuate the host’s
immune response. Some of these impair the cellular path-
ways of antigen processing and presentation, whereas others
serve as decoys, mimicking host molecules crucial to natural
killer (NK)4 or T-cell recognition (1). The genome of MCMV,
which serves as a model for the human virus (HCMV), encodes a
set of proteins that are predicted to be structural analogs of class I
major histocompatibility (MHC-I) glycoproteins (2–4). The
detailed function of each of these viral MHC-I-like molecules
(MHC-Iv) has not yet been determined, but several examples sug-
gest that they either down-regulate host MHC-I or MHC-I-like
molecules or directly bind to NK-cell inhibitory receptors. Thus,
they can interfere with key components of T-cell recognition or
NK-cell activation, therebypromoting virus survival.MHC-Imol-
ecules, transmembrane cell surface receptors consisting of a heavy
chain, a2-microglobulin (2m) light chain, and bound peptides,
are poised for recognition by clonotypic  receptors on CD8T
cells or by inhibitory or activating receptors on NK cells. MHC-I
are classic (Ia) or non-classic (Ib) molecules based on their amino
acidsequencepolymorphism, function, andtissue-specificexpres-
sion. The heavy chain consists of an12 domain unit containing
two -helices set atop an eight-stranded -sheet platform and an
Ig-like 3 domain (5). MHC-Ib molecules exhibit less polymor-
phism,most donotbindpeptide, and they vary in their association
with 2m (6). MHC-Ib proteins function both in immune recog-
nition and in other physiological settings (7).
Only oneMCMV protein, m144, like its HCMV counterpart
UL18 (8), is clearly related to MHC-I based on amino acid
sequence similarity (9). m144 allows virus-infected cells to
evade theNK cell response, but itsmechanismof action and the
nature of any ligand remain unclear. Expression studies of
m144 indicate that, unlike MHC-Ia molecules, it does not
require peptide for cell surface expression (10, 11). The crystal
structure of m144 reveals an MHC-I-like protein, bound to
2m but not associated with peptide, confirming predictions
based on sequence comparison. The molecule is characterized
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by a large angle between 12 and 3, a unique stabilizing
disulfide bond in 12, and relatively loose association of the
heavy chain with 2m (11).
In addition to m144, MCMV encodes the eight molecules of
the m145 family, all of which are predicted to have an MHC-I
protein fold (2–4), despite the lack of significant sequence sim-
ilarity to m144 or to MHC-Ia molecules. Four of the family
members (m145,m152,m155, andm157) function as immuno-
evasins. m145, m152, and m155 down-regulate the cell surface
expression of ligands of the activating receptor NKG2D (12–
15). m152 also causes the retention of MHC-I molecules in the
endoplasmic reticulum-Golgi intermediate compartment (16).
m157 functions by binding theNK inhibitory receptor Ly49I129
in MCMV-sensitive mouse strains such as 129. Alternatively it
can interact with the NK-activating receptor Ly49H in strains
(e.g. C57BL/6) that are resistant to MCMV infection (2, 17).
m157 expression requires neither2mnor peptide (2). Its crys-
tal structure revealed several deviations from theMHC-Ia fold:
an extended, helical N terminus, designated 0, that precedes
the canonical1 helix and imparts a three-helix structure to the
N-terminal 12 domain; a long 2 helix that extends into the
3 domain; short interhelical distances and close interactions
of the 12 domain with 3 resulting in a molecule signifi-
cantly more compact than classic MHC-I; and an 3 domain
whose Ig fold is less twisted than typical Ig folds (18).
The unique functions of m145, m152, m155, and m157 sug-
gest that eachmember of them145 family is important inmod-
ulating the response of the host toMCMV infection. The struc-
tural features of m144 and m157 imply that other members of
the m145 family also may have evolved significant structural
deviations from typical MHC-I to solve novel difficulties in
their encounter with the immune system. An understanding of
the evolution and function of the MHC-I-like molecules of
MCMV demands examination of the cellular expression,
immunological function, and molecular structure of each of
these molecules. To gain further insight into another member
of the m145 family, we have examined m153 in detail. We first
demonstrate that m153 is a functional gene that directs the
expression of its encoded protein to the surface of MCMV-
infected cells. Surface expression is independent of the trans-
porter associated with antigen processing (TAP) or 2m. In
surprising contrast to MHC-I molecules, recombinant soluble
m153 is homodimeric. The crystal structure of m153 described
here reveals the mode of dimerization in addition to other dis-
tinguishing features. Thus, although prediction algorithms
group members of the m145 family together within the broad
MHC-I structural family, the details of the individual structures
show wide variation fromMHC-I and demonstrate the robust-
ness and adaptability of theMHC-I fold in the service of diverse
biological functions.
EXPERIMENTAL PROCEDURES
Cell Lines
NIH3T3, RMA, and RMA-S were grown in Dulbecco’s mod-
ified Eagle’s medium containing 10% fetal bovine serum, 5 
105 M 2-mercaptoethanol, 1 non-essential amino acids (Bio-
Whittaker), and 50 g/ml gentamicin at 37 °C in 5% CO2. R1.1
and R1E were cultured in RPMI containing the same supple-
ments as above. Drosophila S2 cells were maintained in Insect
Express medium (BioWhittaker) supplemented with 50 g/ml
gentamicin except where mentioned otherwise.
Antibodies
Rabbit antiserum was produced against m153 expressed as
inclusion bodies in Escherichia coli. Reduced, denatured SDS-
gel-purified m153 was emulsified in complete Freund adjuvant
prior to immunization. The mouse monoclonal antibody
mAb153.16, generated with the extracellular domain ofmature
m153 (amino acids 1–314) expressed in S2 cells, stains m153-
transfected cells and immunoprecipitates m153 from trans-
fected or virus-infected cells.
Vector Constructs
Insect Cell Expression—cDNA encoding the extracellular
domain of the mature form of m153 (amino acids 1–314) was
PCR-amplified fromMCMV-infected cell culture supernatants
(Smith strain, American Type Culture Collection, catalog no.
VR-1399) using primers 5GGATCCGAGGTCGTGCGGCC-
CGAAGTTAAC and 5GGTACCTCAATGGTGATGGTG-
ATGATGGCTGCCGCGCGGCACCAGGGTCAGTCTC-
GAATCGTTGATCGTC. A BamHI restriction site was
incorporated into the forward primer, and a thrombin cleavage
site (LVPRG), a His6 tag, a termination codon, and a KpnI
restriction site were incorporated into the reverse primer. The
m153 PCR product was directly cloned into the pCR4-
Topo-TA vector (Invitrogen), the sequence was verified, and
then the excised BamHI/KpnI m153 fragment was inserted in
the BglII and KpnI sites of pMT-Bip-V5-His (Invitrogen).
Mammalian Cell Expression—The full-length m153 gene
(encoding amino acids 22–382, including the signal peptide
sequence) was amplified from MCMV-infected cell culture
supernatants and an N-terminal FLAG tag introduced by
sequential PCR. The sequential forward primers used were: A,
5TCAGCGGAGGTCGACTACAAGGATGACGATGACA-
AGGTGCGGCCCGAAGTTAACAGG; B, 5TTGGTTCTC-
ATCTCAGGAGGGTTCTGGGCGTGCGGCTCAGCGGA-
GGTCGACTACAAG; and C, 5GCTACGGGATCCATGATT-
CCCCTTCTCCTTCTGCCGTTGGTTCTCATCTCAGGA-
GGG. The reverse primer was 5TACGCTGAATTCTTACACC-
ACATTCTCCTCCGTATCCGAGCA. 5 BamHI and a 3 EcoRI
restriction sites were incorporated in the forward and reverse
primers, respectively, for subsequent cloning into the pIRES-hr-
GFP-II vector (Stratagene).
BiFC Vectors
Mammalian expression vectors encoding the N-terminal
1–154 residues (N-YFP) or the C-terminal 155–238 residues
(C-YFP) of YFP were a kind gift from Dr. K. Ozato, NICHD,
National Institutes of Health. m153 and m144 were amplified
from existing full-length constructs using primers m153_5YFP
(5ACGGGATCCATGATTCCCCTTCTCCTTCTGCCG) and
m153_3YFP (5ACGGAATTCGCCACCACATTCTCCTCC-
GTATCCG), and m144 was amplified using primers
m144_5YFP (5ACGAGATCTATGAGGGCTCTGGCGCTG)
and m144_3YFP (5ACGGAATTCGCAATGCTGGGATCC-
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GGGACCGTG). The PCRproducts were digested and inserted
into the BglII and EcoRI sites of N-YFP and C-YFP, and the
sequences were verified. The resulting constructs encode
fusion proteins of m153 and m144 linked at their C termini to
either the N- or C-terminal fragments of YFP. A 12- to 13-
amino acid spacer separates the viral proteins from the YFP
fragments.
2m and TAPDependence
The Amaxa nucleofector (Amaxa Biosystems) was used to
introduce the pIRES-hr-GFP II vector (Stratagene) encoding
either FLAG-m153 or H-2Dd into R1.1 and R1E cells (solution
V, program A30) or into RMA and RMA-S cells (solution T,
program A30) according to the manufacturer’s instructions.
18–24 h post transfection the cells were stained for surface
expression of FLAG-tagged m153 with the M2 monoclonal
antibody (Sigma) and a phycoerythrin-labeled anti-mouse IgG1
antibody (Southern Biotech). H-2Dd was detected using the
phycoerythrin-labeled 34-5-8S antibody (BD Biosciences).
Cells were analyzed by flow cytometry (FACSCalibur, BD
Biosciences).
MCMV Infection, Cell Surface Staining, and FACS
70%confluentNIH3T3cellswere infectedwithMCMV-GFP (a
virus containingGFP at an innocuous site (19)) at amultiplicity of
infection of two. Twenty-four hours post infection (p.i.) the cells
were detached with a non-enzymatic cell dissociation solution
(Cellstripper, Cellgro) and resuspended in phosphate-buffered
saline containing 5% fetal calf serum and 0.1%NaN3. F(ab)2 frag-
ments were generated from monoclonal antibody mAb153.16
with the Immunopure IgG1 F(ab)2 kit (Pierce). Infected andunin-
fected cells were incubated with the F(ab)2 followed by anti-
mouse IgG-allophycocyanin. Dead cells were excluded by pro-
pidium iodide gating. Cells were analyzed with a FACSCalibur,
and virus-infected cells were gated on GFP expression.
Bimolecular Fluorescence Complementation (BiFC)
NIH3T3 cells were transfected with 153-N-YFP and 153-C-
YFP or 144-N-YFP and 144-C-YFP using theAmaxa nucleofec-
tor (solutionR, programU30). Cells were then seeded on cham-
bered coverslides and incubated for 48 h at 37 °C. A Leica TCS
AOBS SP2 confocal microscope (Leica Microsystems)
equipped with a 63 1.4 numerical aperture PL APO objective
was used to examine live cells at room temperature for YFP
fluorescence complementation. Leica TCS v2.1547 software
was used to capture the images. After analysis the cells were
detached with trypsin, and the YFP-positive cells were quanti-
fied by flow cytometry.
Immunoprecipitation andWestern Blots
Transiently transfected and virus-infected cell lines were
processed for immunoprecipitation and Western blotting as
detailed in the supplemental “Experimental Procedures.”
Expression and Purification ofm153 in S2 Cells
The pMT-Bip-m153-His construct together with puromycin
and blasticidin resistance-encoding plasmids (10:1:1 ratio by
weight) were transfected into S2 cells using Fugene6 (Roche
Applied Science) according to the manufacturer’s protocol.
48 h after transfection the cells were transferred to selective
medium containing 5 g/ml puromycin (Sigma) and 5 g/ml
blasticidin (Calbiochem). Resistant cells were maintained in
selective medium in shaker cultures (28 °C, 100 rpm). Expres-
sion of m153 was induced with 1 mM CuSO4 at a cell density of
2 107/ml. m153 was purified on a nickel-nitrilotriacetic acid
column (Qiagen) and then subjected to SEC (Shodex KW802.5
or Amersham Biosciences Superdex 75). The His tag was
removed by thrombin cleavage at 37 °C for 2 h, and the protein
was purified by anion exchange chromatography (Mono Q,
Amersham Biosciences). For preparation of a selenomethio-
nine (SeMet) derivative of m153, them153/S2 cells were grown
in Orbigen insect cell medium to 2  107 cells/ml. The cells
were then washed in methionine-free medium (Orbigen) and
starved in thismedium for 6 h under normal growth conditions.
Protein expression was induced by simultaneous addition of 1
mM CuSO4 and 60 g/ml SeMet (Sigma). The SeMet-labeled
protein was purified as described for the native protein.
Crystallization, Structure Determination, and Refinement
Crystals of the SeMet derivative of m153 were grown in
hanging drops at 18 °C over 25% polyethylene glycol 2000
MME, 0.1 M Tris-HCl, pH 8 (Solution 24, The PEGs Suite, Qia-
gen). Addition of 0.5% -D-maltoside to the drops yielded crys-
tals that diffracted to 2.3 Å. Diffraction data for SAD phasing
were collected on a single crystal on beamline X29A at the
National Synchrotron Light Source, Brookhaven, at a wave-
length of 0.9791Å andprocessedwithHKL2000 (20). The auto-
mated SOLVE/RESOLVE scripts as incorporated in the
AutoSol module of the PHENIX suite (21) were used with data
truncated at 2.8 Å to obtain SADphases followed by automated
model building and docking to the m153 sequence. Ambigu-
ously placed residues were rebuilt manually into the SAD-
phased map in Coot as alanines (22). To extend the resolution
to 2.4 Å a molecular replacement search was carried out in
Phaser (23) with the partially built model yielding Z-scores of
11.0 and 23.7 for the rotation and translation functions, respec-
tively, for one dimer in the asymmetric unit. Rigid body refine-
ment specifying 12 and 3 as separate domains yielded a
model with initial R and Rfree of 36.9% and 38.6%, respectively.
Refinement at 2.4 Å was continued in Refmac5 (24) with tight
NCS restraints between chains A and B with further model
building guided by 2Fo  Fc and Fo  Fc maps generated in
Coot. Although data were collected to 2.3 Å, data in the 2.38–
2.3 shell were of insufficient quality and completeness. There-
fore only data to 2.4 Å were used in refinement. Residues in the
231–237 loop, which had little or no electron density, were
omitted from the NCS restraints. Optimal domains for TLS
refinement were identified and input files for TLS refinement
were generated using the TLSMD web server (25). TLS refine-
ment using 10TLS groups per chain decreasedRfree from 29.9%
to 28%. Finally, waters were added with CNS (26), and a final
round of refinement was performed without NCS restraints.
The final model has Rcryst  23% and Rfree  27.9%, includes
residues 2–230 and 238–277 of chain A and residues 5–277 of
chain B and has 57 waters. The atomic coordinates and struc-
ture factors have been deposited in the Protein Data Bank (27)
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under accession number 2O5N.
Buried surface area calculations
were performed in CNS. Figures
were generated using PyMOL,
according to the manufacturer’s
manual (28).
Hinge angles were calculated
using HINGE, a program written by
Peter Sun. HINGE calculates an
ellipsoid (defined by axes a, b, and c)
for each indicated domain and
reports the angle between the long
axes of the adjacent domains as the
hinge angle. HINGE is available at
http://sis.niaid.nih.gov/programs/
hinge.html.
Transient Expression ofWild-type
andMutantm153 in SF9 Cells
Alanine mutations were intro-
duced simultaneously at four resi-
dues (Thr-128, Ser-131, Arg-225,
and Ser-241) in the m153-N-YFP
construct using the QuikChange
Multi mutagenesis kit (Stratagene).
Wild-type and mutated m153 (resi-
dues22–382) genes were PCR-am-
plified from the m153-N-YFP and
m153-N-YFP-mutant constructs
using primers 5CGTCACCCATG-
GCAATTCCCCTTCTCCTTCT-
GCCGTTGGTTCTC and 5ACT-
TCGCTCGAGGGTGAGTCTCG-
AATCGTTGATCGTCCTCTG.
The PCR products were digested
with NcoI and XhoI and inserted
into the corresponding sites of the
pIEx-4 SF9 expression vector
(Novagen). 200 g of m153-pIEx-4
or quadruple mutant-m153-pIEx-4
were transfected into 1 108 expo-
nentially growing SF9 cells in 100ml
with 1 ml of Insect GeneJuice trans-
fection reagent (Novagen). 72 h
after transfection the cell superna-
tants were collected. Wild-type and
quadruple mutant m153 were then
purified on nickel-nitrilotriacetic
acid and SEC columns as described
for S2 insect cell expression.
Analytical Ultracentrifugation
Sedimentation velocity experi-
ments were conducted with a Pro-
teomeLab XLI ultracentrifuge
(Beckman Coulter). 400-l samples
were loaded at concentrations of 0.3
mg/ml for m153 wild-type and 0.5
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and 0.1 mg/ml for the m153 mutant and centrifuged at 50,000
rpm at 20 °C. Sedimentation data were acquired with the Ray-
leigh interference optical system at 1-min intervals, and data
were analyzed using SEDFIT software (29).
RESULTS
m153 Is Expressed on the Surface of MCMV-infected
Fibroblasts—Theopen reading frameof them153 gene predicts
a type I transmembrane glycoprotein with a core molecular
mass of 45 kDa. As a first step in the functional characterization
of m153, we examined its expression inMCMV-infected fibro-
blasts. NIH3T3 cells, infected with MCMV at a multiplicity of
infection of 2, expressed readily detectable levels of m153 at the
cell surface 24 h p.i. as detected by the monoclonal antibody
mAb153.16, specific for the extracellular domain of m153 (Fig.
1A). Uninfected cells did not stainwith this antibody. By immu-
noprecipitationm153was detected in lysates of infected cells as
early as 3 and up to 48 h after infection with protein levels
peaking at 24 h p.i. (data not shown).
Immunoprecipitation of cell lysates followed by SDS-PAGE
and Western blot analysis of m153 revealed an unexpectedly
high apparent molecular mass of 80 kDa, which was decreased
to 45 kDa upon deglycosylation with peptide N-glycosidase F
(Fig. 1B). Such heavy glycosylation is consistent with six pre-
dicted sites for asparaginyl-carbohydrate addition.
Cell Surface Expression of m153 Is Independent of 2m or
TAP Expression—Because theMHC-I fold was predicted for all
members of the MCMV m145 family (4), we next determined
whether m153 shares the requirements of classic MHC-I mole-
cules for 2m and peptide for stable expression. To investigate its
requirement for 2m, we transfected N-terminally FLAG-tagged
m153 (FLAG-m153) into a cell line deficient in 2m (R1E (30)) as
well as its2m-sufficient counterpart (R1.1).m153surfaceexpres-
sion was equivalent in both cell types indicating that m153 does
not require 2m for stable surface expression (Fig. 1C).
To evaluate the requirement for bound peptide, we exam-
ined surface expression ofm153 inRMA-S, aTAP-deficient cell
line that fails to transfer peptides from the cytosol to the endo-
plasmic reticulum (31). MHC-Ia molecules expressed in such
cells are unstable at the cell surface.We transfected RMA-S and
RMA (TAP) cells with FLAG-m153 and evaluated surface
expression of the viral protein in comparison to transfected
H-2Dd, an MHC-Ia molecule (Fig. 1D). TAP deficiency had no
effect on m153 surface expression, whereas expression of
H-2Dd was clearly reduced. We conclude that m153 does not
require 2m or bound peptide for stable surface expression.
MHC-I Fold of m153—To elucidate the structure of m153 an
SeMet derivative was prepared by biosynthetic labeling of the
protein expressed in Drosophila S2 cells. SEC indicated that
solublem153was a dimer (supplemental Fig. S1). Diffraction data
from a single crystal were collected, the structure was solved by
SAD phasing, and the model was refined at 2.4-Å resolution to
final Rcryst and Rfree of 23 and 27.9, respectively (Table 1). There is
a singledimer in theasymmetricunitwithchainsdesignatedAand
B. We observed continuous electron density for residues 2–230
and 238–277 of chain A and residues 5–277 of chain B. No elec-
tron density was observed for theC-terminal residues 278–314 of
either chain, and thesewere omitted from themodel. The average
B-factor was 42Å2 for chain A and 32Å2 for chain B.We selected
chain B to describe the structural features of themonomer as they
relate to the MHC-I fold, because it is more complete and has
lower B-factor values.
The structure of m153 (Fig. 2) reveals basic structural ele-
ments of theMHC-I fold. Them153 12 domain consists of a
unit inwhich the1helix and a discontinuous2helix rest atop
a platform of seven -strands. Three of the strands derive from
FIGURE1.m153expressionat the surfaceofMCMV-infected,2m-deficient, andTAP-deficient cells.A,MCMV-infectedNIH3T3cellswere surface-stained
form153 expression at 24 hpost infection (p.i.). Blue, infected cells plusmAb153.16; black, infected cells plus control antibody; and dashed line, uninfected cells
plusmAb153.16. B, immunoprecipitation andWestern blot analysis ofm153 fromuninfected (lane 1) andMCMV-infected (lane 2) NIH3T3 cell lysates at 24 hp.i.
Immunoprecipitation of m153 from transfected NIH3T3 cells (immunoprecipitation, mAb153.16; Western blot, anti-m153 rabbit serum). Samples were mock
treated (lane 3) or treatedwithpeptideN-glycosidase F (lane 4) before SDS-PAGEandWesternblot.C, R1.1 (2m) andR1E (2m) orD, RMA (TAP) andRMA-S
(TAP) cells were transfected with FLAG-m153-pIRES-GFP or H-2Dd-pIRES-GFP as a control. 18 h post transfection surface levels of m153 and H-2Dd were
determined as described under “Experimental Procedures.” The number of GFP-positive cells indicates transfection efficiency. The percentage surface expres-
sion is shown in the bar graphs on the right (percentage of GFP cells that stain for either FLAG-M2 or H-2Dd).
TABLE 1
Data collection, refinement, and validation statistics
Data collection
Space group P21
Unit cell dimensions
a, b, c 61.7, 78.2, 62,7
, ,  90, 90.4, 90.0
Molecules per asymmetric unit 2
Resolution (Å) 2.3
Total observations 335,101
Unique reflections 26,191
Completeness (%)a 97.5 (94.2)
I/Ia 9.7 (2.0)
Rsyma,b 0.081 (0.44)
Refinement
Resolution range 62.75–2.4
Reflections
Working set 23,443
Test set 1183
Rcryst (%)c 23.0
Rfree (%)c 27.9
Number of non-H protein atoms 4,393
Number of water molecules 57
Carbohydrate chains 3
r.m.s. deviations from ideality
Bond lengths (Å) 0.01
Bond angles (°) 1.318
Average B values (Å2) A, B
Main chain 42.2, 32.2
Side chain 42.5, 32.7
Whole chain 42.4, 32.4
Overall 37.6
Model validation: Ramachandran plot statistics
(Procheck) (%)
Most favored 87.8
Allowed 12.2
Generous 0
Disallowed 0
a Values in parentheses are statistics for the highest resolution shell used in refine-
ment (2.48-2.38 Å).
b Rsym(I)Ij I/Ij, where Ij is the intensity of the jth observation of a reflec-
tion and I is the mean intensity from multiple measurements of that reflection.
c Rcryst Fo  Fc/Fo, where Fo and Fc are the observed and calculated struc-
ture factor amplitudes, respectively. Rfree is as for Rcryst but calculated for a ran-
domly selected 5.0% of reflections not included in the refinement. Procheck was
used for model validation (49).
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the 1 domain and four from 2. The fourth -strand of the 1
domain, commonly found inMHC-Ia and -Ib molecules, is not
observed in m153. Unlike either MHC-Ia or -Ib molecules the
C-terminal end of the 2-helix extends downward into a third
helix (designatedH2b) that connects the12 domainwith the
Ig-like 3 domain (Fig. 2A).
Several structural features of the m153 monomer differ sub-
stantially from classicMHC-I molecules. Most striking is the N
terminus, extended by 20 residues, which starts adjacent to the
G strand of the 3 domain, forming a short  strand. From
there it extends upward alongside the H2b helix and continues
as the first strand of the platform beginning at residue 21 (Fig.
2A). This feature is absent in all MHC-I molecules described
thus far and differs substantially fromm157, whose extendedN
terminus forms instead a third, short helix adjacent to the 2
helix (Fig. 3, A and C). A unique disulfide between Cys-16 and
Cys-171 anchors the extended N terminus of m153 to the H2b
helix (Fig. 2D). In addition several hydrogen bonds link the
extended N-terminal strand (residues 6–15) and the loop
between platform strands 2 and 3. Other hydrogen bonds
link the extended N terminus to the H2b helix and the 3 F-G
loop and serve to further stabilize the structure (Fig. 2C). The
1 and 2 helices are shorter than those observed in MHC-Ia
proteins and are closely juxtaposed
above the  sheet floor. Close inter-
actions between these helices pre-
clude the binding of peptide or
other ligand (Fig. 2B), in agreement
with cellular expression studies
indicating that m153 does not
depend on bound peptide for stabil-
ity (Fig. 1D). The platform is stabi-
lized by a second unusual disulfide
(Cys-101 toCys-108),whichconnects
strands 5 and 6 of the floor (Fig.
2D). A similar bond is seen in m157
(Cys-103 to Cys-112), but MHC-Ia
moleculespreserveadisulfidebond in
the same region,which links-strand
5 of the platform to the2 helix (Cys-
101 to Cys-164) (32). The presence of
the unusual disulfide bonds in m153
was confirmed by mass spectrometry
(supplemental Figs. S3 and S4).
The 3 domain of m153 has a
C2-type Ig-fold, which is character-
ized by amore compact domain and
shorter intercysteine spacing than
the C1 or V-type fold (33). The A, B,
and E strands make up one sheet of
the domain, and the C, C, F, and G
strands make up the opposite sheet
(Fig. 2A). The canonical Ig-domain
disulfide bond (Cys-203 to Cys-255)
connects strands B and F. Searches
against the DALI data base (34)
identifiedm144, also with a C2-type
Ig-fold, and CD1d as proteins with
3 domains that are structurally most closely related to m153.
The difference between the strand dispositions in the 3
domains of m153 and m157 is indicated by the relatively high
r.m.s.d. of 2.3 Å for the superposition of 67 C atoms. The 3
domain of m153 has longer -strands that exhibit the charac-
teristic -sandwich twist, whereas the m157 3 domain has
strands that are shorter and form flatter sheets (Fig. 3C). The
terminal residues that were modeled in both structures adopt
different conformations, in m153 they form a short -helix,
whereas in m157 the C-terminal strand forms a circular loop
that contacts both sheets of the 3 domain (18).
In Fig. 3 we compare the 12 domain of m153 chain B to
that of m157, H-2Kb (35), rat FcRn (36), and the NKG2D ligand
Rae-1 (37). The 1 and H2b helices of m153 and m157 are in
equivalent positions, whereas their2helices differ. TheN-termi-
nal end of them157 2 helix was notmodeled due to lack of elec-
tron density (18). The m153 2 helix starts with two full turns
(residues 140–146), followed by an extended region that stretches
along the platform ending in two turns of helix before bending
sharply downward to continue as the H2b helix.
The maximal distance between the 1 and 2 helices of
m153 is 8.1 Å compared with 16.8 Å inH-2Kb (Fig. 3A). Surface
representations of the 12 domains of m153 and H-2Kb (Fig.
FIGURE 2. Conserved and unique features of them153monomer. A, side view ofm153 chain B. The 1, 2,
and H2b helices, the 3 domain, N and C termini are labeled, and the disulfide bonds are in yellow. N-terminal
residues 2–20 are gray. B, top view of the seven -strand platform and 12 helixes of m153. C, extended N
terminus of m153 showing extensive interactions between the N terminus (gray) and H2b helix, loops in the
12 domain and the G strand of the 3 domain (cyan). Hydrogen bonds are in black. D, side view of m153
monomer. Two unique disulfide bonds link the N-terminal fragment to the H2b helix (C16-C171) and the 5
platform strand to the loop connecting the 5 and 6 strands (C101-C108). Electron density around the
uniquedisulfides is contoured at 1.25. The conserveddisulfidebond (Cys-203–255) is located in the Ig-like3
domain.
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3B) illustrate the lack of a peptide-binding groove in m153. The
groove region of m153 is comparable to that of Rae-1 and FcRn,
twomolecules thatalsodonotbindpeptide.Themaximaldistance
betweenCatomsof the1and2helicesofRae-1andFcRnare
8.2 Å and 9.2Å, respectively. The1 helices ofm153, Rae-1, and
FcRn have a similar arrangement on the platform, but the m153
FIGURE 3.Comparison ofm153withm157, H-2Kb, Rae-1, and rat neonatal FcR.A, ribbon diagrams of the platformdomains ofm153,m157, Rae1, FcRn,
and H-2Kb. The width of the groove of each molecule is indicated in angstroms and was measured at both ends and in the middle at comparable residues of
the -helices. B, surface representation of the peptide-binding domain of H-2Kb (groove shownwithout any peptide) and the corresponding region of m153.
Black rectangles indicate the groove. C, comparison of m153 chain B with m157 and H-2Kb. The 12 and H2b-helices, 3-domain, and N and C termini are
labeled. PDB accession codes are: 2NYK, 2VAA, 1JFM, and 3FRU.
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helix is shorter. The m153 platform has seven strands compared
with the eight found in classicMHC-I proteins (Fig. 3A).
The hinge angle between 12 and 3 of m153 chain B is 76°,
which is within the range of theMHC-I molecules H-2Kb, CD1d,
and T22 (71–74°) but is smaller than that of m157 (81°), MICA
(116°), and m144 (99°) (supplemental Table S1). The m153 3
domainmakesextensivecontactswith theH2bhelix,with the loop
connecting strands 2 and 3 of the platform as well as with the
loopconnecting3and1.Theburied surface areabetween12
and 3 of m153 is 1777 Å2, which is considerably larger than the
analogous interfaces in m157 (1265 Å2) and H-2Kb (455 Å2).
m153 Dimer—SEC of the insect cell-expressed extracellular
portion of m153 indicated that the molecule formed a stable
non-covalent homodimer (supplemental Fig. S1), an observa-
tion confirmed by equilibriumand velocity sedimentation (data
not shown). The crystal structure reveals the details of the
mode of dimerization. Two MHC-I-like chains of m153 are
organized in a head-to-tail arrangement forming a compact
dimer (Fig. 4A). The two chains are almost identical (r.m.s.d. of
0.624 Å for superposition over 268 C atoms). The interaction
of the platform domain of one subunit with the 3 domain of the
other imparts a coronal shape forming a central cavity with a vol-
ume of	9500Å3. The conical cavitymeasures 46Å 35Å at the
top narrowing down to 22 Å 18 Å.
It is closedoff at thebottomwhere the
Lys-115 side chains of each subunit
areonly 4Åapart.Wepropose anori-
entation of the m153 dimer with
respect to the plasma membrane
shown in Fig. 4B. The subunits lie
with their long axes parallel to the
membrane and with the 1 helices
closest to the membrane. In this ori-
entation the C termini of both chains
point toward the membrane (Fig. 4B,
lower). The 37 C-terminal residues
for which no electron density was
observed in either chain may form a
flexible stalk connecting the ectodo-
main to the transmembrane region.
m153 conserves only two of the 31
2m-contacting residues present in
H-2Kb. It is evident from the dimer
orientation of m153 that association
with 2m would be sterically hin-
dered, an observation consistent with
the 2m independence of m153
expression (Fig. 1C).
Three sugar moieties were mod-
eled in the m153 structure (at Asn-
107 in chains A and B and Asn-252
in chain B). These all point upward
from the dimer away from the cell
surface. Mass spectrometry indi-
cated glycosylation at five of the six
predicted N-linked carbohydrate
addition sites (data not shown).
These sites occur in both 12 and
3 and are distributed around the periphery of them153 dimer,
with none in the central cavity or at the proposed membrane
proximal face of the molecule (Fig. 4A). The electrostatic sur-
face of the m153 dimer reveals four nearly symmetrical basic
patches inside the central cavity, and two highly acidic regions
on the bottom surface that are formed by the loop that connects
theA andB strands of the3 domain and theC-terminal-hel-
ical fragment (Fig. 4C).
The m153 dimer interface is formed by parallel -strand
interactions between the platform (8 strand) of one subunit
and the 3 domain (C strand) of the second subunit (Fig. 5A),
resulting in two extended, twisted -sheets of 12 strands each
that form the core of the dimer. The two interfaces are not
perfectly symmetrical as 21 residues of chain A and 22 residues
of chain B are involved in dimerization. There are 16 hydrogen
bonds at the interface,most of which represent backbone inter-
actions (Fig. 5B). In addition there are 114 non-bonded con-
tacts. The area buried at the dimer interface is 1088Å2, which is
larger than that observed in HLA-G (676 Å2), which forms a
disulfide-linked MHC-Ib dimer (Fig. 5C). The shape comple-
mentarity index of the dimer was calculated as 0.72, which is
higher than that of most antibody-antigen interfaces (0.62–
0.68), consistent with the stability of the homodimer (shape
FIGURE 4.Overall structure of them153dimer.A, ribbon diagramof them153 dimer as viewed from the top.
Chain A, salmon; chain B, cyan. The 12 helices, the 3 Ig-like domains, and N and C termini are labeled. The
dashed line in chain A indicates a disordered loop. Blue sticks, carbohydrates observed in the crystal structure;
yellow sticks,N-linked glycosylation sites confirmed bymass spectrometry. B, two 90° rotations reveal different
side views of them153 dimer, and its proposed orientation on the cell membrane. C, top and bottom views of
the electrostatic surface representation of the m153 dimer (red, acidic; blue, basic).
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complementarity index 1 represents a perfect fit (38)). To con-
firm the observed interface we tested the effects of mutating four
interface residues Thr-128, Ser-131, Arg-225, and Ser-241, all of
which formside-chain/side-chainhydrogenbonds, toalanine (Fig.
5C). Wild-type m153 and a mutant containing these four alanine
mutationswereexpressedandanalyzedbyultracentrifugationand
SEC. Themutant protein had a smaller sedimentation coefficient
indicating disruption of the dimer (Fig. 5D). SEC confirmed the
smaller size ofmutantm153 (supplemental Fig. S5). Thus the four
mutations destabilized the m153 dimer and confirm the mode of
dimerization visualized in the structure.
Full-length m153 Is Dimeric in Mammalian Cells—To
exclude the possibility that dimerization is a result of the engi-
neering of soluble m153, we used two approaches to examine
m153 in mammalian cells. In BiFC (39) experiments we fused
full-length m153 to either N- or C-terminal segments of YFP.
Although transfectants of either construct alone did not show
fluorescence, co-transfection of m153-N-YFP andm153-C-YFP
resulted in the complementation of YFP fluorescence in trans-
fected cells (Fig. 6A and supplemental Fig. S2), indicating that
m153 does form dimers. Cells transfected with YFP fusion con-
structs of m144, a monomericMHC-Iv protein, showed less than
1% YFP-positive cells. In a second approach we co-transfected
N-terminal FLAG- and HA-tagged m153 in NIH3T3 cells. Suc-
cessful immunoprecipitation of m153 with anti-FLAG antibodies
and Western blot detection with anti-HA antibodies confirmed
that m153 dimerizes in transfected fibroblasts (Fig. 6B). Together
these results provide strong evidence that m153 is a dimer when
expressed as the full-length protein in mammalian cells.
Comparison of m153 to them145 Family—m153 is related by
sequence to proteins of the mouse and rat CMV 145 families
but has no direct homolog in the rat virus (3, 40). The m153
protein is most closely related to m152 (28% identity), a known
regulator of MHC-I and NKG2D ligands in MCMV-infected
cells (14, 16). Fig. 7 shows a sequence alignment of the m145
family highlighting shared structural features. Based on com-
parison of m153 andm157, we suggest that the core of the viral
MHC-I-like fold of the m145 family is composed of the 12
domain, the extendedH2b helix, and an Ig-like3 domain. The
number of platform strands, the length of 2 on top of the
FIGURE 5.Dimer interface ofm153.A, chain A-platform/Chain B-3 interface indicated by the boxed region. B, stereo viewof the parallel strand interactions
between the8 strand of chain A (salmon) and theG strandof chain B (cyan). The nine hydrogenbonds are shown as black dashes. Oxygen, red; nitrogen, blue.
C, molecular surface representation of m153 dimer (center). At the left and right the two chains were rotated 75° out of the plane of the paper (or screen) to
display the buried interaction surfaces (white). The positions of the interface residues thatweremutated to alanine (Thr-128, Ser-131, Arg-225, and Ser-241) are
shown in red.D, mutations at the interface destabilize them153dimer. Sedimentation coefficients ofwild-typem153 (black, 0.3mg/ml) andquadruplemutant
m153 (T128A,S131A,R225A,S241A; red, 0.5 mg/ml; green, 0.1 mg/ml) as determined by sedimentation velocity ultracentrifugation.
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platform, and the position of some disulfide bonds may vary. A
crucial stabilizing interaction for this MHC-I-like fold is that
between Glu-70 (1 helix), Arg-166, and Trp-167 (H2b helix).
Apart from a cysteine in the3 domain, these three residues are
the only amino acids that are conserved throughout the mouse
and rat 145 families, emphasizing the importance of this salt
bridge. Within the m145 family stretches of similarities are
found in  helix and  sheet regions, whereas loop regions and
the 3 domain show less conservation. The m153 residues
involved in dimerization are not conserved in the rest of the
family consistent with our observation that m151 and m152 do
not dimerize in solution.5 Thus dimerization may be unique to
m153. Five family members contain cysteines that align with
those of the unusual m153 Cys-16 to Cys-171 disulfide. The
Cys-101 to Cys-108 and Cys-203 to Cys-255 disulfides are also
conserved among some of the family members. The limited
sequence similarity of the N- and C-terminal regions of the
extracellular domains of the m145 family members likely indi-
cates a structural divergence in these parts of these molecules.
DISCUSSION
MHC-I molecules play a crucial role in the protection of the
host against virus infection. Not only are MHC-I molecules
essential for the detection of infection and priming of the cyto-
toxic CD8 T-cell response, but their presence on the cell sur-
face protects healthy cells from attack by NK cells. Viral mole-
cules with an MHC-I-like structure are likely to be excellent
decoys for inhibitory NK receptors and may be able to interact
with numerous molecules involved in the immune response. It
is therefore not surprising that herpesviruses have incorporated
MHC-I-like molecules in their arsenal of immunoevasins.
Human, mouse, and rat CMV encode MHC-I-like molecules
that exhibit different levels of similarity to MHC-Ia molecules (3,
40).HCMVencodes theMHC-IhomologUL18,whichbindsboth
2mandpeptide andengages the inhibitory receptorLIR-1 (41). It
also encodes UL142, which functions
to inhibit NK cell lysis, has less
sequence similarity to MHC-I, and is
predicted to consist of only the
MHC-I 12 domain (42). MCMV
encodes proteins like m144 that can
associate with 2m, and others like
m153 and m157, members of the
m145 family, that are expressedwith-
out 2m. It is likely that several host
genes have been captured by viruses
during the course of co-evolution
(43). In the case of the MHC-I viral
homologs it is probable that the
closely related MHC-I genes like
m144 and r144 were originally
acquired from the host and that the
distantly relatedm145 and r145 fam-
ilies arose via gene duplication and
expansion of the 144 gene shaped by
the selective pressures of the host immune response.
The crystal structure of MCMV m153 provides an example
of the versatility of the MHC-I fold and is the first report of an
obligate non-covalent dimer composed of two MHC-I-like
chains. Together with the recently reported m157 structure, it
highlights both the conserved and divergent features of the
m145 family. The m153 monomer retains the core MHC-I
characteristics, a -sheet platform that supports two -helices
and an Ig-like3domain, but it exploits several structural adap-
tations to yield a stable molecule in the absence of peptide and
2m. Three main features combine to stabilize the m153 mon-
omer: 1) the closely spaced1 and2 helices on the platformdo
not form a groove and alleviate the need for peptide binding; 2)
the extended H2b helix bridges the 12 domain to the 3
domain; and 3) numerous interdomain contacts and two
unique disulfide bonds (Cys-16 to Cys-171 and Cys-101 to Cys-
108) stabilize the structure. Some of these features are shared
among the other members of the m145 family. Whereas m157
is linked to the cell membrane via a glycophosphatidylinositol
moiety and functions as a monomer (2), m153 has a bona fide
transmembrane region and a large (47-amino acid) intracellu-
lar domain. We have shown that m153 is a stable dimer when
expressed in mammalian cells, and the crystal structure of the
soluble ectodomain reveals the mode of dimerization.
Dimerization is unusual for MHC-I molecules. Although
dimers of some classic MHC-I molecules have been reported, i.e.
HLA-B27 (44) and HLA-G (45), these are disulfide-linked and
their physiological relevance remains unclear. A non-disulfide
linked dimer has been observed in crystals of the rat FcRn. Unlike
m153, the twoMHC-Imolecules of the FcRn interact via their 3
and2mdomains, utilizing extensive protein-protein and protein
carbohydrate interactionsat the interface (36). In them157crystal,
a dimer of the same orientation asm153 is formedwith one of the
symmetry-related molecules. In m157 this dimer interface is
formed by anti-parallel  strand interactions between the 6
strandof theplatformand theDstrandof the3domain.Thus the
same chain orientation but an opposite sheet of the 3 domain
(strands A, B, E, and D) is utilized in the observed crystal packing.
5 J. Mans, K. Natarajan, A. Balbo, P. Schuck, C. T. Tiemessen, and D. H. Margu-
lies, unpublished observation.
FIGURE 6.m153 forms a homodimer in mammalian cells. A, BiFC analysis. m153 constructs, fused to the N-
or C-terminal portions of YFP, were cotransfected in NIH3T3 cells, and the live cells were examined by confocal
microscopy for fluorescence complementation after 48 h. As a negative control YFP fusion constructs ofMCMV
m144 were co-transfected. Left, YFP channel; right, overlay of the YFP on the differential interference contrast
(DIC) channel. Quantification of the number of YFP-positive cells is shown in supplemental Fig. S2. B, co-
immunoprecipitationof differentially taggedm153. FLAG-m153 (F) or F plusHA-m153 (FHA) constructswere
transfected in NIH3T3 cells. 24-h post transfection post nuclear cell lysates were immunoprecipitated with
anti-FLAG antibodies and detected on a Western blot with anti-FLAG (left), anti-m153 rabbit antibodies (mid-
dle), or HA-specific antibodies (right).
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To gain insight into possible ligand binding sites onm153 we
have examined regions corresponding to known interaction
sites on murine MHC-I like molecules. These include the
CD8 binding site (3 domain residues 220–228 and residues
of the 12 domain platform), the Ly49A NK receptor binding
site (“site 2,” including residues from the 3 domain, the 12
domain platform, and key residues of 2m), and the region of
the FcRn-Fc interaction site (N-terminal portions of the 2
domain and of 2m) (7). The compact nature of the m153
dimer, its lack of 2m association, and the regions that are
masked by dimerization make it unlikely that any of the above
mentioned sites are available for ligand binding.
Becausem153 is clearly related toother immunoevasinsbyboth
amino acid sequence and structure, it may be expected also to
function to subvert the host immune response. Several features
strongly indicate that m153 has a significant role in the viral life
cycle: 1) Several regions of the m153 sequence are conserved
among related molecules with known immunoregulatory func-
tion. m152 and m155 conserve the Cys-16 to Cys-171 disulfide,
and m152 and m145, as well as m157, conserve the 5-6 Cys-
101 to Cys-108 disulfide. 2) This is a readily expressed viral glyco-
protein, easily detected both intracellularly and at the cell surface
in MCMV-infected fibroblasts. 3) Heteroduplex mobility assay
and DNA sequence analysis have been used to examine the levels
of sequencevariationofanumberofMCMVgenesof isolates from
wild mice and laboratory strains. The MHC-Iv immunoevasins
m144,m155, andm157havesignificantvariation,whereasm152 is
highly conserved (17, 46). m153, like m152, is highly conserved
amongmany strains showing little variation by both heteroduplex
mobility assay and sequencing.6 Such conservation implies not
only a role in viral survival but suggests thatm153, likem152,may
interact with an invariant site on a host molecule (46). Further
experiments will explore the identification of cellular and molec-
ular ligandsand test thecontributionofm153 toacuteandchronic
stages of viral infection.
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m145  110                                                                                    RW                            V Y C C V L L L L   AA L FLRSRCG R E TFNATFWYG V TIVLNETV LKYNPAFVNG..TEHTLIYNKTAEK KNYAE....GRDTDL KNKVTS YP LKVYKA K GGPNSLKTR RTSN....
m150   73                                                                                    RW                            V Y C C V V L L L I   IM L FSAAVHN T E DFAPQL.VG L VHTADGTN R...SAIVTVRDKKKVVIADHSSDN TKFTT....DLD SV RRNEVS HG SSTRLK K AAPEHLEVS HVS....V
m157   93                                                                                    RW                            V Y C C V V I I   L L FDTQRIC R A LFLGFD.VI D YHTTDTVR A........YTGQTGKINIQGSGKFSTSDAK....EIGTYM KSNVRE KN RSTVQK KQ AYMNATEVE WYN.....
                 .               ........                                                                       m157
β0 β1 β2 β3 α1
β5' β6' β7' β8' α2 α2 H2b A
α0 β1 β2 β3 β4 α1
β5 β6 β7 α2 H2b A
+
-
                                                                                                                 m153
m153  196        C                                                                                                          M T PL Y M V L V C I S G W LIEMDIVQ Q T QV K H T WSAGRDSRAIA SADYYTDIE ASYLPVNRSQ.ILNTT E T SS ......... TVR RFSEEMVAAS.....
m152  193        C                                                                                                          M T PL Y I L M V T I S G W VRGNGYVS T R QV A N S ANGVDIYKYMR YSG..GRLK EAWLDLRDLNGS DFAFV S PT ......... YAT KYSEYPQQSP.....
m17   208        C                                                                                                          I S PA F A M M V T C T G W L..NGTVR R E PS R M G N......TPYG YTRYNYTTG SSTVNVEETN.E NST DFQ LF ........R SYE PTPGHVRGCE.....
m155  194        C                                                                                                          V S V I S W VDGRNLTK G K EGRRRMH A TD......ECGNIGYAGGRLNYTGGGFYLEAVTE APGLVCTVRTT......... LGS RNATSERVRRKSV..
m151  181        C                                                                                                          A PV M I A I N C I G W I.MTNGVV E TVSS ILW T VG...SDVQLN SSVFDNTNN SSVRAFSSVSPN SPR E ICSA ......... NVT RQPNSSAATT.....
m145  213        C                                                                                                          V T PL F I I V S C I S...NTTI E W YA Y S E EVAGLPPVKGE SKSWFTIYMRVQN..QTSDSDL KSI K R SVRGACKDVRHPRYVPPPITTSPTTTALT...
m150  174        C                                                                                                          V S PL F V V A A S C I S G W LGRHGFFC S W PA P D T RGGGLRSVSLN SRRFFSDTV LLNDFTTSSFEP DLV V R SV ......... TVT TTPSHDEAK......
m157  188        C                                                                                                          V S V F V L V C V S G W V.TTGLTT V T RSN P T E S......LNTNSSAIVTDEST DCQILTVKAPGSHAQR Y T SL ......... KGV TPPSQYRTKRVPVNI
                                                                                                                 m157
B C C' E F G
B C D E F H IG
α1
α2 α3
FIGURE 7. Amino acid sequence alignment of the m145 family. The predicted extracellular domains of all m145 family members (Refseq: NC_004065 (3))
were aligned using ClustalW (47) and optimized based on m153 and m157 structure. Secondary structure elements of m153 are shown above and those of
m157 shown below the alignment. Cysteines involved in disulfide bonds are indicated by red (m153) and blue (m157) squares, and the respective pairs are
indicated. Cysteines that are not conserved throughout the family, but are predicted to formdisulfide bonds are boxed in red. Residues involved in a salt bridge
(Glu-70 and Arg-166) are also indicated. N-Linked glycosylation sites are indicated by green stars. The residues involved in m153 dimer interface contacts are
indicated by blue ovals. The figure was generated with ESPRIPT (48).
Expression and Structure of MCMVm153
NOVEMBER 30, 2007•VOLUME 282•NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 35257
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Novem
ber 30, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
3. Rawlinson, W. D., Farrell, H. E., and Barrell, B. G. (1996) J. Virol. 70,
8833–8849
4. Smith, H. R., Heusel, J. W., Mehta, I. K., Kim, S., Dorner, B. G., Naidenko,
O. V., Iizuka, K., Furukawa, H., Beckman, D. L., Pingel, J. T., Scalzo, A. A.,
Fremont, D.H., andYokoyama,W.M. (2002)Proc. Natl. Acad. Sci. U. S. A.
99, 8826–8831
5. Bjorkman, P. J., and Parham, P. (1990) Annu. Rev. Biochem. 59, 253–288
6. Natarajan, K., Li, H., Mariuzza, R. A., and Margulies, D. H. (1999) Rev.
Immunogenet. 1, 32–46
7. Margulies, D. H., Natarajan, K., Rossjohn, J., and McCluskey, J. (2007) in
Fundamental Immunology (Paul, W. E., ed) Lippincott, Williams, and
Wilkins, Philadelphia, in press
8. Beck, S., and Barrell, B. G. (1988) Nature 331, 269–272
9. Farrell, H. E., Vally, H., Lynch, D. M., Fleming, P., Shellam, G. R., Scalzo,
A. A., and Davis-Poynter, N. J. (1997) Nature 386, 510–514
10. Chapman, T. L., and Bjorkman, P. J. (1998) J. Virol. 72, 460–466
11. Natarajan, K., Hicks, A., Mans, J., Robinson, H., Guan, R., Mariuzza, R. A.,
and Margulies, D. H. (2006) J. Mol. Biol. 358, 157–171
12. Hasan, M., Krmpotic, A., Ruzsics, Z., Bubic, I., Lenac, T., Halenius, A.,
Loewendorf, A., Messerle, M., Hengel, H., Jonjic, S., and Koszinowski,
U. H. (2005) J. Virol. 79, 2920–2930
13. Krmpotic, A., Hasan, M., Loewendorf, A., Saulig, T., Halenius, A., Lenac,
T., Polic, B., Bubic, I., Kriegeskorte, A., Pernjak-Pugel, E., Messerle, M.,
Hengel, H., Busch, D. H., Koszinowski, U. H., and Jonjic, S. (2005) J. Exp.
Med. 201, 211–220
14. Lodoen, M., Ogasawara, K., Hamerman, J. A., Arase, H., Houchins, J. P.,
Mocarski, E. S., and Lanier, L. L. (2003) J. Exp. Med. 197, 1245–1253
15. Lodoen, M. B., Abenes, G., Umamoto, S., Houchins, J. P., Liu, F., and
Lanier, L. L. (2004) J. Exp. Med. 200, 1075–1081
16. Ziegler, H., Thale, R., Lucin, P., Muranyi,W., Flohr, T., Hengel, H., Farrell,
H., Rawlinson, W., and Koszinowski, U. H. (1997) Immunity 6, 57–66
17. Voigt, V., Forbes, C. A., Tonkin, J. N., Degli-Esposti, M. A., Smith, H. R.,
Yokoyama, W. M., and Scalzo, A. A. (2003) Proc. Natl. Acad. Sci. U. S. A.
100, 13483–13488
18. Adams, E. J., Juo, Z. S., Venook, R. T., Boulanger, M. J., Arase, H., Lanier,
L. L., and Garcia, K. C. (2007) Proc. Natl. Acad. Sci. U. S. A. 104,
10128–10133
19. Mathys, S., Schroeder, T., Ellwart, J., Koszinowski, U.H.,Messerle,M., and
Just, U. (2003) J. Infect. Dis. 187, 988–999
20. Otwinowski, Z., and Minor, W. (1997)Methods Enzymol. 276, 307–326
21. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., Mc-
Coy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., and
Terwilliger, T. C. (2002)Acta Crystallogr. D. Biol. Crystallogr. 58, 1948–1954
22. Emsley, P., andCowtan, K. (2004)ActaCrystallogr. D. Biol. Crystallogr. 60,
2126–2132
23. Read, R. J. (2001) Acta Crystallogr. D. Biol. Crystallogr. 57, 1373–1382
24. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997)Acta Crystallogr.
D. Biol. Crystallogr. 53, 240–255
25. Painter, J., and Merritt, E. A. (2005) Acta Crystallogr. D. Biol. Crystallogr.
61, 465–471
26. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P.,
Grosse-Kunstleve, R.W., Jiang, J. S., Kuszewski, J., Nilges,M., Pannu,N. S.,
Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta
Crystallogr. D. Biol. Crystallogr. 54, 905–921
27. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig,
H., Shindyalov, I. N., and Bourne, P. E. (2000) Nucleic Acids Res. 28,
235–242
28. DeLano,W. L. (ed) (2002) The PyMOLUser’s Manual, DeLano Scientific,
Palo Alto, CA
29. Schuck, P. (2000) Biophys. J. 78, 1606–1619
30. Allen, H., Fraser, J., Flyer, D., Calvin, S., and Flavell, R. (1986) Proc. Natl.
Acad. Sci. U. S. A. 83, 7447–7451
31. Townsend, A., Ohlen, C., Foster, L., Bastin, J., Ljunggren, H. G., and Karre,
K. (1989) Cold Spring Harbor Symp. Quant. Biol. 54, 299–308
32. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger,
J. L., and Wiley, D. C. (1987) Nature 329, 506–512
33. Halaby, D. M., and Mornon, J. P. (1998) J. Mol. Evol. 46, 389–400
34. Holm, L., and Sander, C. (1996) Science 273, 595–603
35. Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., andWilson,
I. A. (1992) Science 257, 919–927
36. Burmeister, W. P., Gastinel, L. N., Simister, N. E., Blum, M. L., and Bjork-
man, P. J. (1994) Nature 372, 336–343
37. Li, P., McDermott, G., and Strong, R. K. (2002) Immunity 16, 77–86
38. Lawrence, M. C., and Colman, P. M. (1993) J. Mol. Biol. 234, 946–950
39. Hu, C. D., Chinenov, Y., and Kerppola, T. K. (2002)Mol. Cell 9, 789–798
40. Vink, C., Beuken, E., and Bruggeman, C. A. (2000) J. Virol. 74, 7656–7665
41. Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L., and
Hsu, M. L. (1997) Immunity 7, 273–282
42. Wills,M. R., Ashiru,O., Reeves,M. B.,Okecha,G., Trowsdale, J., Tomasec,
P., Wilkinson, G.W., Sinclair, J., and Sissons, J. G. (2005) J. Immunol. 175,
7457–7465
43. Alcami, A., and Koszinowski, U. H. (2000) Trends Microbiol. 8, 410–418
44. Bowness, P. (2002) Rheumatology (Oxford) 41, 857–868
45. Shiroishi, M., Kuroki, K., Ose, T., Rasubala, L., Shiratori, I., Arase, H.,
Tsumoto, K., Kumagai, I., Kohda,D., andMaenaka, K. (2006) J. Biol. Chem.
281, 10439–10447
46. Smith, L. M., Shellam, G. R., and Redwood, A. J. (2006) Virology 352,
450–465
47. Chenna, R., Sugawara,H., Koike, T., Lopez, R., Gibson, T. J., Higgins, D.G.,
and Thompson, J. D. (2003) Nucleic Acids Res. 31, 3497–3500
48. Gouet, P., Courcelle, E., Stuart, D. I., and Metoz, F. (1999) Bioinformatics
15, 305–308
49. Laskowski, R. A., Moss, D. S., and Thornton, J. M. (1993) J. Mol. Biol. 231,
1049–1067
Expression and Structure of MCMVm153
35258 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 48•NOVEMBER 30, 2007
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on Novem
ber 30, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
